CollPlant Renews Distribution Agreement

CollPlant Renews Distribution Agreement

for its Soft Tissue Repair

Product Vergenix STR with Arthrex a World Leader in Orthopedics

Distribution in Europe, Middle East,

India and Africa for the treatment of tendinopathy

Ness Ziona, Israel, March 18, 2019 --

CollPlant (Nasdaq: CLGN), a regenerative medicine company, today announced that it has renewed its exclusive distribution agreement

with Arthrex for Vergenix STR for the treatment of tendinopathy. The original distribution agreement, which commenced in

December 2016, is now extended through December 31, 2020, with Arthrex serving as the exclusive distributor of CE Marked Vergenix STR

in Europe, the Middle East, India and certain African countries.

Vergenix STR is an injectable gel

comprised of cross-linked bioengineered recombinant human type I collagen, rhCollagen, combined with autologous platelet-rich plasma

(PRP). Forming a collagen-fibrin matrix that serves as a scaffold for cell recruitment, Vergenix STR is intended to

accelerate healing in the treatment of tendinopathy, including tennis elbow, rotator cuff, patellar tendon, Achilles tendon, and

A recently published clinical trial in

the Journal of Shoulder and Elbow Surgery, showed the mean Patient-Rated

Tennis Elbow Evaluation score had a 59% improvement (reduction) from baseline at 6 months following treatment with Vergenix STR.

"CollPlant is pleased to extend our

distribution agreement with Arthrex, a world leader in the orthopedic market. The extension of this agreement is a direct result

of the excellent product performance and market acceptance of Vergenix STR. Leveraging on the Post Marketing Surveillance

clinical data, we now plan on expanding the distribution of Vergenix STR to other territories, including Asia" stated

CollPlant CEO, Yehiel Tal.

Vergenix STR is primarily

made of crosslinked recombinant human collagen (rhCollagen) and is intended to be combined with platelet-rich plasma (PRP), a concentrated

blood plasma derived from the patient's own blood that contains high levels of platelets, which are critical to the healing

process. Platelets contain growth factors which are responsible for stimulating tissue generation and repair, including soft tissue

repair, bone regeneration, development of new blood vessels, and stimulation of the healing process. Upon administration, CollPlant's

Vergenix STR serves as a scaffold to support cell adhesion and proliferation involved in tendon healing, while

maintaining growth factor-containing PRP in the vicinity of the injury. After injection into the affected area, the product forms

a viscous gel matrix, holding the platelet concentrate in place. The formed matrix then has the ability to release growth factors

in a controlled manner and with controlled biodegradation time, thereby enabling optimal healing.

Arthrex is a leading

medical orthopedic products company. The company operates throughout the world and has developed over 10,000

products and medical procedures. Arthrex's corporate headquarters is located in Southwest Florida. Additional

locations include a global division in Munich, Germany as well as several subsidiaries and distribution centers throughout,

among others, Europe - Middle East - Africa (EMEA). Also see the following Arthrex website:

CollPlant is a regenerative medicine company

focused on 3D bioprinting of tissues and organs, medical aesthetics, and on developing and commercializing tissue repair products

for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that

is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for the

diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk

product line is ideal for 3D bioprinting of tissues and organs. We recently entered into a licensing agreement with United Therapeutics,

whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

CollPlant's unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and

a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

For more information about CollPlant, visit

Safe Harbor Statements

This press release may include forward-looking

statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives

plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that

CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized

by terminology such as "believes," "hopes," "may," "anticipates," "should,"

"intends," "plans," "will," "expects," "estimates," "projects,"

"positioned," "strategy" and similar expressions and are based on assumptions and assessments made in

light of management's experience and perception of historical trends, current conditions, expected future developments and

other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject

to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements.

Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated

in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses

and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's

expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on

its rhCollagen based BioInk, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical

trial results; regulatory action with respect to rhCollagen based BioInk, VergenixSTR, and VergenixFG including but not limited

to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope

of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based BioInk,

VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements

with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain

strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all

aspects of its product manufacturing; the scope of protection we are able to establish and maintain for intellectual property

rights and the Company's ability to operate its business without infringing the intellectual property rights of others;

the overall global economic environment; the impact of competition and new technologies; general market, political, and economic

conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's

strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant

is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F

filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking

statements contained in this press release are made as of the date of this press release and reflect CollPlant's current

views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise

any forward-looking statements, whether as a result of new information, future events or otherwise.